Swiss biotech start-up Baxiva AG will receive $3 million to develop a multivalent glycoconjugate vaccine that targets invasive extraintestinal pathogenic E coli infections.
IDSA emphasized that the VICP be funded appropriately to compensate injured individuals without putting an infeasible burden on vaccine manufacturers that could severely jeopardize vaccine access.
Seven people have been hospitalized, and severe complications have been reported for at least two cases.
The decline in resistant E coli corresponds with a 50% cut in sales of antibiotics for use in food-producing animals in the United Kingdom from 2014 through 2021.
The most common pathogen-animal pair was Salmonella and poultry, followed by Cryptosporidium and ruminants and Salmonella and turtles.
Surveillance data from 33 nations show that resistance to ampicillin, tetracyclines, and sulfonamides remains "persistently high" in Salmonella and Campylobacter.
Portuguese biotechnology company Immunethep is receiving $2 million from CARB-X to develop a conjugate peptide-based vaccine against E coli.
Of the 13 outbreaks with confirmed cases of foodborne illness, all but 1 involved either Listeria, Salmonella, or Escherichia coli.
Review of data from the trial found that the vaccine was not sufficiently effective at preventing invasive E coli disease compared with placebo.
Both fresh whole and sliced cucumbers from Mexico were recalled in a 113-case Salmonella outbreak.
